Recurrent epithelial ovarian cancer and hormone therapy

Table 1 Therapeutic effect of antiestrogens and aromatase inhibitors on relapsed ovarian cancer n (%)

Ref.	Agents	Dose and usage	The kind of study	No. of patients	CR
Schwartz et al[12]	Tamoxifen	Oral 20 mg daily, maximun is 3210 mg	Phase II	13	0
Weiner et al[13]	Tamoxifen	Oral 40 mg for 7 d, then 20 mg po daily	Phase II	31	1 (3.2)
Hatch et al[9]	Tamoxifen	Oral 20 mg daily	Phase II Platinum sensitive/resistant	105	10 (9.5)
Tropé et al[11]	Tamoxifen	Oral 30 mg or 40 mg daily	Phase II Platinum sensitive resistant	66	2 (3)
Argenta et al[14]	Tamoxifen	Day 1500 mg im day 15 250 mg im day 29 250 mg im	Phase II Platinum sensitive resistant	26	1 (4)
Bowman et al[15]	Letrozole	Oral 2.5 mg daily	Phase II	50	0
Papadimitriou et al[18]	Letrozole	Oral 2.5 mg daily	Phase II Platinum sensitive/resistant	27	1 (4)
Smyth et al[16]	Letrozole	Oral 2.5 mg daily	Phase II Platinum sensitive/resistant	33	0
Ramirez et al[17]	Letrozole	Oral 2.5 mg daily	Phase II Platinum resistant	31	0
del Carmen et al[19]	Letrozole	Oral 1 mg daily	Phase II	53	0

CR: Complete response.